Logotipo do repositório
 

Publicação:
Clinical evaluation of amitriptyline for the control of chronic pain caused by temporomandibular joint disorders

dc.contributor.authorRizzatti-Barbosa, Célia M.
dc.contributor.authorNogueira, Mariana T. P.
dc.contributor.authorDe Andrade, Eduardo D.
dc.contributor.authorAmbrosano, Gláucia M. B.
dc.contributor.authorDe Albergaria Barbosa, José R. [UNESP]
dc.contributor.institutionDepto. de Protese e Periodontia
dc.contributor.institutionUniversidade de São Paulo (USP)
dc.contributor.institutionIntl. Assoc. for the Study of Pain
dc.contributor.institutionIntl. Assoc. for Dental Research
dc.contributor.institutionUniversidade Estadual de Campinas (UNICAMP)
dc.contributor.institutionIntl. Assoc. for Dental Researchers
dc.contributor.institutionDental School of Piracicaba
dc.contributor.institutionBrazilian Soc. for Dental Research
dc.contributor.institutionInternational Biometric Society
dc.contributor.institutionUniversidade Estadual Paulista (Unesp)
dc.contributor.institutionA. C. Camargo Cancer Center
dc.date.accessioned2014-05-27T11:20:41Z
dc.date.available2014-05-27T11:20:41Z
dc.date.issued2003-07-01
dc.description.abstractTemporomandibular disorder (TMD) is characterized by a combination of symptoms affecting the temporomandibular joint and/or chewing muscles. The two most common clinical TMD symptoms are pain and dysfunction. Pain is usually caused by dysfunction, and emergency therapy has focused on controlling it. Recent investigations into TMD have led to the recommendation of antidepressants as a supporting treatment against constant neuralgic pain. The aim of this double-blind study was to verify the efficiency of antidepressants (amitriptyline) as a support in the treatment of chronic TMD pain. Twelve female volunteers presenting chronic TMD pain were divided into two groups and treated for 14 days: Group 1 with 25 mg/day of amitriptyline and Group 2 with a placebo. The intensity of pain and discomfort was evaluated daily, using a visual analog scale (VAS), over a period of seven days preceding the treatment (baseline), during the 14-day treatment, and for seven days after the treatment. The results revealed a significant reduction of pain and discomfort in Group 1 (75%) compared to Group 2 (28%) during the three weeks beginning at baseline (p< 0.01). Amitriptyline proved to be an efficient alternative treatment for chronic pain in TMD patients. Copyright © 2003 by CHROMA, Inc.en
dc.description.affiliationDepto. de Protese e Periodontia, Av. Limeira, 901, CEP 13.414-018 Piracicaba, SP
dc.description.affiliationState University of São Paulo
dc.description.affiliationIntl. Assoc. for the Study of Pain
dc.description.affiliationIntl. Assoc. for Dental Research
dc.description.affiliationState University of Campinas
dc.description.affiliationDept. of Prosthesis and Periodontol. Unicamp
dc.description.affiliationIntl. Assoc. for Dental Researchers
dc.description.affiliationDepartment of Physiological Sciences State University of Campinas
dc.description.affiliationPharmacology Laboratory Dental School of Piracicaba
dc.description.affiliationBrazilian Soc. for Dental Research
dc.description.affiliationInternational Biometric Society
dc.description.affiliationJulio Mesquita Filho State U.
dc.description.affiliationA.C. Camargo Hospital, São Paulo
dc.description.affiliationDepartment of Oral Medicine UNICAMP
dc.description.affiliationDental Clinic UNICAMP Dental College
dc.description.affiliationUnespJulio Mesquita Filho State U.
dc.format.extent221-225
dc.identifierhttp://www.ncbi.nlm.nih.gov/pubmed/12889679
dc.identifier.citationCranio, v. 21, n. 3, p. 221-225, 2003.
dc.identifier.issn0886-9634
dc.identifier.lattes1664688357804299
dc.identifier.scopus2-s2.0-0141574344
dc.identifier.urihttp://hdl.handle.net/11449/67350
dc.language.isoeng
dc.relation.ispartofCranio
dc.relation.ispartofjcr1.094
dc.relation.ispartofsjr0,374
dc.rights.accessRightsAcesso restrito
dc.sourceScopus
dc.subjectamitriptyline
dc.subjectantidepressant agent
dc.subjecttricyclic antidepressant agent
dc.subjectanalgesia
dc.subjectchronic pain
dc.subjectclinical article
dc.subjectclinical trial
dc.subjectcomparative study
dc.subjectcontrolled clinical trial
dc.subjectcontrolled study
dc.subjectdouble blind procedure
dc.subjectdrug efficacy
dc.subjectfemale
dc.subjecthuman
dc.subjectpain assessment
dc.subjecttemporomandibular joint disorder
dc.subjecttreatment outcome
dc.subjectvisual analog scale
dc.subjectchronic disease
dc.subjectface pain
dc.subjectrandomized controlled trial
dc.subjectAmitriptyline
dc.subjectAntidepressive Agents, Tricyclic
dc.subjectChronic Disease
dc.subjectDouble-Blind Method
dc.subjectFacial Pain
dc.subjectFemale
dc.subjectHumans
dc.subjectPain Measurement
dc.subjectTemporomandibular Joint Disorders
dc.subjectTreatment Outcome
dc.titleClinical evaluation of amitriptyline for the control of chronic pain caused by temporomandibular joint disordersen
dc.typeArtigo
dspace.entity.typePublication
unesp.author.lattes1664688357804299
unesp.campusUniversidade Estadual Paulista (UNESP), Instituto de Ciência e Tecnologia, São José dos Campospt
unesp.departmentBiociências e Diagnóstico Bucal - ICTpt

Arquivos